BMY
HealthcareBristol-Myers Squibb Company
$58.93-0.03 (-0.04%)
Prev Close
$58.95
Open
$59.67
High
$60.06
Low
$58.75
Volume
5.65M
Market Cap
$120.05B
P/E
17.08
Div Yield
0.04%
Over the past 12 months, insider activity at Bristol-Myers Squibb Company (BMY) has been dominated by selling, with 1 insider purchase totaling $202.2K and 13 insider sales totaling $3.68M. The most recent insider transaction was by Hickey Benjamin (President, RayzeBio Org.), who sold $209.7K worth of shares on Feb 1, 2026. Bristol-Myers Squibb Company operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $120.05B.
Buys (12M)
1
$202.2K
Sells (12M)
13
$3.68M
Net Activity
Net Seller
$3.47M
Active Insiders
8
last 12 mo
BMY Price Chart
BMY Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 3,810 | $55.05 | $209.7K | 0 |
| Feb 1, 2026↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 833 | $55.05 | $45.9K | 0 |
| Nov 4, 2025↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 1,238 | $46.07 | $57.0K | 0 |
| Nov 4, 2025↗ | Shanahan Karin | EVP, Chief Supply Chain & Ops | Sell | 3,213 | $46.07 | $148.0K | 0 |
| Nov 1, 2025↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 2,665 | $46.07 | $122.8K | 0 |
| Oct 2, 2025↗ | Gallman Cari | EVP, General Counsel | Sell | 2,332 | $45.73 | $106.6K | 0 |
| Sep 2, 2025↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 56,000 | $47.33 | $2.65M | 0 |
| Sep 1, 2025↗ | Short Bartie Wendy | EVP, Corporate Affairs | Sell | 632 | $47.18 | $29.8K | 0 |
| Aug 2, 2025↗ | Short Bartie Wendy | EVP, Corporate Affairs | Sell | 378 | $44.23 | $16.7K | 0 |
| Aug 1, 2025↗ | Gallman Cari | EVP, General Counsel | Sell | 543 | $44.23 | $24.0K | 0 |
| Jun 3, 2025↗ | Short Bartie Wendy | EVP, Corporate Affairs | Sell | 3,334 | $48.09 | $160.3K | 0 |
| May 9, 2025↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 97 | $38.16 | $3.7K | 0 |
| Apr 25, 2025↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,250 | $47.58 | $202.2K | 0 |
| Apr 1, 2025↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 1,692 | $59.55 | $100.8K | 0 |
| Mar 12, 2025↗ | Hoch Lynelle | President, Cell Therapy Org. | Sell | 2,248 | $63.11 | $141.9K | 0 |
| Mar 12, 2025↗ | Holzer Phil M | SVP and Controller | Sell | 1,820 | $63.11 | $114.9K | 0 |
| Mar 12, 2025↗ | Lenkowsky Adam | EVP, Chief Commercial Officer | Sell | 6,065 | $63.11 | $382.8K | 0 |
| Mar 12, 2025↗ | Poole Ahn Amanda | EVP, Chief People Officer | Sell | 2,273 | $63.11 | $143.4K | 0 |
| Mar 12, 2025↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 7,173 | $63.11 | $452.7K | 0 |
| Mar 10, 2025↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 21,797 | $63.11 | $1.38M | 0 |
| Mar 10, 2025↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 20,935 | $63.11 | $1.32M | 0 |
| Mar 10, 2025↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 1,940 | $63.11 | $122.4K | 0 |
| Mar 10, 2025↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 16,056 | $63.11 | $1.01M | 0 |
| Mar 10, 2025↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 17,710 | $63.11 | $1.12M | 0 |
| Mar 10, 2025↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 6,711 | $63.11 | $423.5K | 0 |
| Mar 10, 2025↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 3,610 | $63.11 | $227.8K | 0 |
| Mar 4, 2025↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 1,630 | $59.62 | $97.2K | 0 |
| Feb 20, 2025↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Buy | 2,000 | $55.05 | $110.1K | 0 |
| Feb 19, 2025↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,823 | $54.85 | $100.0K | 0 |
| Feb 4, 2025↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 833 | $58.95 | $49.1K | 0 |
| Feb 1, 2025↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 3,725 | $58.95 | $219.6K | 0 |
| Nov 4, 2024↗ | Holzer Phil M | SVP and Controller | Sell | 700 | $55.62 | $38.9K | 0 |
| Nov 1, 2024↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 1,488 | $54.32 | $80.8K | 0 |
| Nov 1, 2024↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,830 | $54.67 | $100.1K | 0 |
| Oct 2, 2024↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 1,648 | $53.76 | $88.6K | 0 |
| Aug 1, 2024↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 384 | $48.17 | $18.5K | 0 |
| Apr 1, 2024↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 1,196 | $52.99 | $63.4K | 0 |
| Mar 10, 2024↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 19,407 | $53.79 | $1.04M | 0 |
| Mar 10, 2024↗ | Caforio Giovanni | Executive Chair of the Board | Sell | 67,823 | $53.79 | $3.65M | 0 |
| Mar 10, 2024↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 18,522 | $53.79 | $996.3K | 0 |
| Mar 10, 2024↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 696 | $53.79 | $37.4K | 0 |
| Mar 10, 2024↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 13,649 | $53.79 | $734.2K | 0 |
| Mar 10, 2024↗ | Hoch Lynelle | President, Cell Therapy Org. | Sell | 1,308 | $53.79 | $70.4K | 0 |
| Mar 10, 2024↗ | Holzer Phil M | SVP and Controller | Sell | 1,389 | $53.79 | $74.7K | 0 |
| Mar 10, 2024↗ | Lenkowsky Adam | EVP, Chief Commercial Officer | Sell | 4,323 | $53.79 | $232.5K | 0 |
| Mar 10, 2024↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 16,660 | $53.79 | $896.1K | 0 |
| Mar 10, 2024↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 1,965 | $53.79 | $105.7K | 0 |
| Mar 10, 2024↗ | Poole Ahn Amanda | EVP, Chief Human Resources | Sell | 1,375 | $53.79 | $74.0K | 0 |
| Feb 1, 2024↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 754 | $48.67 | $36.7K | 0 |
| Dec 5, 2023↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Buy | 2,000 | $49.78 | $99.6K | 0 |
| Dec 2, 2023↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 1,350 | $50.10 | $67.6K | 0 |
| Dec 2, 2023↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 3,730 | $50.10 | $186.9K | 0 |
| Dec 2, 2023↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 274 | $50.10 | $13.7K | 0 |
| Nov 28, 2023↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Buy | 3,071 | $48.86 | $150.0K | 0 |
| Nov 20, 2023↗ | Samuels Theodore R. II | Director | Buy | 8,500 | $49.81 | $423.4K | 0 |
| Aug 24, 2023↗ | Powell Ann | EVP, Chief Human Resources | Sell | 17,986 | $61.25 | $1.10M | 0 |
| Aug 3, 2023↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 732 | $61.14 | $44.8K | 0 |
| Jul 1, 2023↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 4,787 | $63.95 | $306.1K | 0 |
| Jul 1, 2023↗ | Weese Michelle | EVP, Corporate Affairs | Sell | 682 | $63.95 | $43.6K | 0 |
| Jun 3, 2023↗ | Lenkowsky Adam | EVP, Chief Commercial Officer | Sell | 551 | $65.66 | $36.2K | 0 |
| May 3, 2023↗ | VESSEY RUPERT | EVP & President, Research | Sell | 50,385 | $67.06 | $3.38M | 0 |
| May 2, 2023↗ | Greenlees Sharon | SVP & Controller | Sell | 346 | $68.10 | $23.6K | 0 |
| Apr 1, 2023↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 3,198 | $69.31 | $221.7K | 0 |
| Apr 1, 2023↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 1,692 | $69.31 | $117.3K | 0 |
| Mar 10, 2023↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 34,620 | $65.71 | $2.27M | 0 |
| Mar 10, 2023↗ | Caforio Giovanni | Board Chair and CEO | Sell | 137,989 | $65.71 | $9.07M | 0 |
| Mar 10, 2023↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 41,331 | $65.71 | $2.72M | 0 |
| Mar 10, 2023↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 22,395 | $65.71 | $1.47M | 0 |
| Mar 10, 2023↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 34,104 | $65.71 | $2.24M | 0 |
| Mar 10, 2023↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 1,243 | $65.71 | $81.7K | 0 |
| Mar 10, 2023↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 14,040 | $65.71 | $922.6K | 0 |
| Mar 10, 2023↗ | Powell Ann | EVP, Chief Human Resources | Sell | 16,810 | $65.71 | $1.10M | 0 |
| Mar 10, 2023↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 914 | $65.71 | $60.1K | 0 |
| Mar 10, 2023↗ | VESSEY RUPERT | EVP & President, Research | Sell | 38,498 | $65.71 | $2.53M | 0 |
| Mar 10, 2023↗ | Weese Michelle | EVP, Corporate Affairs | Sell | 594 | $65.71 | $39.0K | 0 |
| Feb 6, 2023↗ | Caforio Giovanni | Board Chair and CEO | Sell | 240,000 | $74.65 | $17.92M | 0 |
| Feb 6, 2023↗ | Powell Ann | EVP, Chief Human Resources | Sell | 11,183 | $74.69 | $835.3K | 0 |
| Feb 1, 2023↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 731 | $71.23 | $52.1K | 0 |
| Dec 2, 2022↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 1,349 | $81.13 | $109.4K | 0 |
| Dec 2, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 4,498 | $81.13 | $364.9K | 0 |
| Dec 2, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 4,498 | $81.13 | $364.9K | 0 |
| Nov 9, 2022↗ | Powell Ann | EVP, Chief Human Resources | Sell | 16,250 | $80.45 | $1.31M | 0 |
| Nov 7, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 45,910 | $78.88 | $3.62M | 0 |
| Sep 20, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $69.71 | $1.74M | 0 |
| Sep 15, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 50,000 | $71.84 | $3.59M | 0 |
| Sep 14, 2022↗ | Powell Ann | EVP, Chief Human Resources | Sell | 25,000 | $70.75 | $1.77M | 0 |
| Sep 13, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 133,951 | $71.30 | $9.55M | 0 |
| Jul 1, 2022↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 4,786 | $76.84 | $367.8K | 0 |
| Jul 1, 2022↗ | Weese Michelle | EVP, Corporate Affairs | Sell | 682 | $76.84 | $52.4K | 0 |
| Jun 13, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 30,000 | $74.04 | $2.22M | 0 |
| Jun 6, 2022↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 65,000 | $74.89 | $4.87M | 0 |
| Apr 1, 2022↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 3,333 | $73.82 | $246.0K | 0 |
| Mar 21, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $71.52 | $1.79M | 0 |
| Mar 16, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 74,559 | $69.25 | $5.16M | 0 |
| Mar 14, 2022↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 29,532 | $69.20 | $2.04M | 0 |
| Mar 14, 2022↗ | Santiago Karen Murphy | SVP & Controller | Sell | 6,577 | $69.20 | $455.1K | 0 |
| Mar 10, 2022↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 34,545 | $68.42 | $2.36M | 0 |
| Mar 10, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 158,890 | $68.42 | $10.87M | 0 |
| Mar 10, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 9,222 | $68.42 | $631.0K | 0 |
| Mar 10, 2022↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 5,205 | $68.42 | $356.1K | 0 |
| Mar 10, 2022↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 44,901 | $68.42 | $3.07M | 0 |
| Mar 10, 2022↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 1,875 | $68.42 | $128.3K | 0 |
| Mar 10, 2022↗ | Powell Ann | EVP, Chief Human Resources | Sell | 20,369 | $68.42 | $1.39M | 0 |
| Mar 10, 2022↗ | Santiago Karen Murphy | SVP & Controller | Sell | 6,223 | $68.42 | $425.8K | 0 |
| Mar 10, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 8,751 | $68.42 | $598.7K | 0 |
| Mar 1, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 10,381 | $68.63 | $712.4K | 0 |
| Mar 1, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 10,303 | $68.63 | $707.1K | 0 |
| Feb 24, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 30,000 | $67.00 | $2.01M | 0 |
| Feb 4, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 1,312 | $64.99 | $85.3K | 0 |
| Dec 31, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 24,246 | $62.35 | $1.51M | 0 |
| Dec 31, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 23,033 | $62.35 | $1.44M | 0 |
| Dec 16, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 19,298 | $61.99 | $1.20M | 0 |
| Dec 2, 2021↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 1,350 | $55.41 | $74.8K | 0 |
| Dec 2, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 4,498 | $55.41 | $249.2K | 0 |
| Dec 2, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 4,498 | $55.41 | $249.2K | 0 |
| Nov 22, 2021↗ | von Autenried Paul | EVP, Chief Information Officer | Sell | 51,134 | $57.18 | $2.92M | 0 |
| Sep 20, 2021↗ | Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $60.64 | $1.52M | 0 |
| Aug 12, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 99,691 | $66.95 | $6.67M | 0 |
| Aug 3, 2021↗ | Powell Ann | EVP, Chief Human Resources | Sell | 23,280 | $68.57 | $1.60M | 0 |
| Aug 2, 2021↗ | Caforio Giovanni | Chairman and CEO | Sell | 20,000 | $68.58 | $1.37M | 0 |
| Aug 1, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 23,736 | $67.87 | $1.61M | 0 |
| Jul 30, 2021↗ | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Sell | 2,466 | $67.90 | $167.4K | 0 |
| Jul 30, 2021↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 29,390 | $68.04 | $2.00M | 0 |
| Jul 30, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 158,393 | $68.07 | $10.78M | 0 |
| Jul 30, 2021↗ | von Autenried Paul | EVP, Chief Information Officer | Sell | 25,000 | $68.06 | $1.70M | 0 |
| Jul 1, 2021↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 4,786 | $66.56 | $318.6K | 0 |
| Jul 1, 2021↗ | Santiago Karen Murphy | SVP & Controller | Sell | 547 | $66.56 | $36.4K | 0 |
| Jun 3, 2021↗ | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 738 | $64.80 | $47.8K | 0 |
| May 10, 2021↗ | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 1,118 | $65.00 | $72.7K | 0 |
| May 10, 2021↗ | Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | Sell | 15,000 | $65.25 | $978.8K | 0 |
| May 8, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 7,994 | $64.44 | $515.1K | 0 |
| May 5, 2021↗ | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Sell | 3,119 | $64.21 | $200.3K | 0 |
| May 5, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 30,546 | $64.29 | $1.96M | 0 |
| Apr 1, 2021↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 2,952 | $62.93 | $185.8K | 0 |
| Mar 22, 2021↗ | Caforio Giovanni | Chairman and CEO | Sell | 25,000 | $62.20 | $1.55M | 0 |
| Mar 10, 2021↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 12,851 | $60.93 | $783.0K | 0 |
| Mar 10, 2021↗ | Caforio Giovanni | Chairman and CEO | Sell | 112,233 | $60.93 | $6.84M | 0 |
| Mar 10, 2021↗ | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Sell | 1,910 | $60.93 | $116.4K | 0 |
| Mar 10, 2021↗ | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 2,192 | $60.93 | $133.6K | 0 |
| Mar 10, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 4,329 | $60.93 | $263.8K | 0 |
| Mar 10, 2021↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 1,978 | $60.93 | $120.5K | 0 |
| Mar 10, 2021↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 31,200 | $60.93 | $1.90M | 0 |
| Mar 10, 2021↗ | Powell Ann | EVP, Chief Human Resources | Sell | 14,329 | $60.93 | $873.1K | 0 |
| Mar 10, 2021↗ | Santiago Karen Murphy | SVP & Controller | Sell | 2,662 | $60.93 | $162.2K | 0 |
| Mar 10, 2021↗ | Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | Sell | 14,589 | $60.93 | $888.9K | 0 |
| Mar 10, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 3,505 | $60.93 | $213.6K | 0 |
| Mar 10, 2021↗ | von Autenried Paul | EVP, Chief Information Officer | Sell | 10,017 | $60.93 | $610.3K | 0 |
| Mar 1, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 8,573 | $61.63 | $528.4K | 0 |
| Mar 1, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 8,944 | $61.63 | $551.2K | 0 |
BMY Insider Buying Activity
The following table shows recent insider purchases of Bristol-Myers Squibb Company (BMY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 25, 2025↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,250 | $47.58 | $202.2K | 0 |
| Feb 20, 2025↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Buy | 2,000 | $55.05 | $110.1K | 0 |
| Feb 19, 2025↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,823 | $54.85 | $100.0K | 0 |
| Nov 1, 2024↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,830 | $54.67 | $100.1K | 0 |
| Dec 5, 2023↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Buy | 2,000 | $49.78 | $99.6K | 0 |
| Nov 28, 2023↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Buy | 3,071 | $48.86 | $150.0K | 0 |
| Nov 20, 2023↗ | Samuels Theodore R. II | Director | Buy | 8,500 | $49.81 | $423.4K | 0 |
BMY Insider Selling Activity
The following table shows recent insider sales of Bristol-Myers Squibb Company (BMY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 3,810 | $55.05 | $209.7K | 0 |
| Feb 1, 2026↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 833 | $55.05 | $45.9K | 0 |
| Nov 4, 2025↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 1,238 | $46.07 | $57.0K | 0 |
| Nov 4, 2025↗ | Shanahan Karin | EVP, Chief Supply Chain & Ops | Sell | 3,213 | $46.07 | $148.0K | 0 |
| Nov 1, 2025↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 2,665 | $46.07 | $122.8K | 0 |
| Oct 2, 2025↗ | Gallman Cari | EVP, General Counsel | Sell | 2,332 | $45.73 | $106.6K | 0 |
| Sep 2, 2025↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 56,000 | $47.33 | $2.65M | 0 |
| Sep 1, 2025↗ | Short Bartie Wendy | EVP, Corporate Affairs | Sell | 632 | $47.18 | $29.8K | 0 |
| Aug 2, 2025↗ | Short Bartie Wendy | EVP, Corporate Affairs | Sell | 378 | $44.23 | $16.7K | 0 |
| Aug 1, 2025↗ | Gallman Cari | EVP, General Counsel | Sell | 543 | $44.23 | $24.0K | 0 |
| Jun 3, 2025↗ | Short Bartie Wendy | EVP, Corporate Affairs | Sell | 3,334 | $48.09 | $160.3K | 0 |
| May 9, 2025↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 97 | $38.16 | $3.7K | 0 |
| Apr 1, 2025↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 1,692 | $59.55 | $100.8K | 0 |
| Mar 12, 2025↗ | Hoch Lynelle | President, Cell Therapy Org. | Sell | 2,248 | $63.11 | $141.9K | 0 |
| Mar 12, 2025↗ | Holzer Phil M | SVP and Controller | Sell | 1,820 | $63.11 | $114.9K | 0 |
| Mar 12, 2025↗ | Lenkowsky Adam | EVP, Chief Commercial Officer | Sell | 6,065 | $63.11 | $382.8K | 0 |
| Mar 12, 2025↗ | Poole Ahn Amanda | EVP, Chief People Officer | Sell | 2,273 | $63.11 | $143.4K | 0 |
| Mar 12, 2025↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 7,173 | $63.11 | $452.7K | 0 |
| Mar 10, 2025↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 21,797 | $63.11 | $1.38M | 0 |
| Mar 10, 2025↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 20,935 | $63.11 | $1.32M | 0 |
| Mar 10, 2025↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 1,940 | $63.11 | $122.4K | 0 |
| Mar 10, 2025↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 16,056 | $63.11 | $1.01M | 0 |
| Mar 10, 2025↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 17,710 | $63.11 | $1.12M | 0 |
| Mar 10, 2025↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 6,711 | $63.11 | $423.5K | 0 |
| Mar 10, 2025↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 3,610 | $63.11 | $227.8K | 0 |
| Mar 4, 2025↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 1,630 | $59.62 | $97.2K | 0 |
| Feb 4, 2025↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 833 | $58.95 | $49.1K | 0 |
| Feb 1, 2025↗ | Hickey Benjamin | President, RayzeBio Org. | Sell | 3,725 | $58.95 | $219.6K | 0 |
| Nov 4, 2024↗ | Holzer Phil M | SVP and Controller | Sell | 700 | $55.62 | $38.9K | 0 |
| Nov 1, 2024↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 1,488 | $54.32 | $80.8K | 0 |
| Oct 2, 2024↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 1,648 | $53.76 | $88.6K | 0 |
| Aug 1, 2024↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 384 | $48.17 | $18.5K | 0 |
| Apr 1, 2024↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 1,196 | $52.99 | $63.4K | 0 |
| Mar 10, 2024↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 19,407 | $53.79 | $1.04M | 0 |
| Mar 10, 2024↗ | Caforio Giovanni | Executive Chair of the Board | Sell | 67,823 | $53.79 | $3.65M | 0 |
| Mar 10, 2024↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 18,522 | $53.79 | $996.3K | 0 |
| Mar 10, 2024↗ | Gallman Cari | EVP, Corporate Affairs | Sell | 696 | $53.79 | $37.4K | 0 |
| Mar 10, 2024↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 13,649 | $53.79 | $734.2K | 0 |
| Mar 10, 2024↗ | Hoch Lynelle | President, Cell Therapy Org. | Sell | 1,308 | $53.79 | $70.4K | 0 |
| Mar 10, 2024↗ | Holzer Phil M | SVP and Controller | Sell | 1,389 | $53.79 | $74.7K | 0 |
| Mar 10, 2024↗ | Lenkowsky Adam | EVP, Chief Commercial Officer | Sell | 4,323 | $53.79 | $232.5K | 0 |
| Mar 10, 2024↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 16,660 | $53.79 | $896.1K | 0 |
| Mar 10, 2024↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 1,965 | $53.79 | $105.7K | 0 |
| Mar 10, 2024↗ | Poole Ahn Amanda | EVP, Chief Human Resources | Sell | 1,375 | $53.79 | $74.0K | 0 |
| Feb 1, 2024↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 754 | $48.67 | $36.7K | 0 |
| Dec 2, 2023↗ | BOERNER CHRISTOPHER S. | Chief Executive Officer | Sell | 1,350 | $50.10 | $67.6K | 0 |
| Dec 2, 2023↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 3,730 | $50.10 | $186.9K | 0 |
| Dec 2, 2023↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 274 | $50.10 | $13.7K | 0 |
| Aug 24, 2023↗ | Powell Ann | EVP, Chief Human Resources | Sell | 17,986 | $61.25 | $1.10M | 0 |
| Aug 3, 2023↗ | Plenge Robert M | EVP, Chief Research Officer | Sell | 732 | $61.14 | $44.8K | 0 |
| Jul 1, 2023↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 4,787 | $63.95 | $306.1K | 0 |
| Jul 1, 2023↗ | Weese Michelle | EVP, Corporate Affairs | Sell | 682 | $63.95 | $43.6K | 0 |
| Jun 3, 2023↗ | Lenkowsky Adam | EVP, Chief Commercial Officer | Sell | 551 | $65.66 | $36.2K | 0 |
| May 3, 2023↗ | VESSEY RUPERT | EVP & President, Research | Sell | 50,385 | $67.06 | $3.38M | 0 |
| May 2, 2023↗ | Greenlees Sharon | SVP & Controller | Sell | 346 | $68.10 | $23.6K | 0 |
| Apr 1, 2023↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 3,198 | $69.31 | $221.7K | 0 |
| Apr 1, 2023↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 1,692 | $69.31 | $117.3K | 0 |
| Mar 10, 2023↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 34,620 | $65.71 | $2.27M | 0 |
| Mar 10, 2023↗ | Caforio Giovanni | Board Chair and CEO | Sell | 137,989 | $65.71 | $9.07M | 0 |
| Mar 10, 2023↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 41,331 | $65.71 | $2.72M | 0 |
| Mar 10, 2023↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 22,395 | $65.71 | $1.47M | 0 |
| Mar 10, 2023↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 34,104 | $65.71 | $2.24M | 0 |
| Mar 10, 2023↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 1,243 | $65.71 | $81.7K | 0 |
| Mar 10, 2023↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 14,040 | $65.71 | $922.6K | 0 |
| Mar 10, 2023↗ | Powell Ann | EVP, Chief Human Resources | Sell | 16,810 | $65.71 | $1.10M | 0 |
| Mar 10, 2023↗ | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Sell | 914 | $65.71 | $60.1K | 0 |
| Mar 10, 2023↗ | VESSEY RUPERT | EVP & President, Research | Sell | 38,498 | $65.71 | $2.53M | 0 |
| Mar 10, 2023↗ | Weese Michelle | EVP, Corporate Affairs | Sell | 594 | $65.71 | $39.0K | 0 |
| Feb 6, 2023↗ | Caforio Giovanni | Board Chair and CEO | Sell | 240,000 | $74.65 | $17.92M | 0 |
| Feb 6, 2023↗ | Powell Ann | EVP, Chief Human Resources | Sell | 11,183 | $74.69 | $835.3K | 0 |
| Feb 1, 2023↗ | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Sell | 731 | $71.23 | $52.1K | 0 |
| Dec 2, 2022↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 1,349 | $81.13 | $109.4K | 0 |
| Dec 2, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 4,498 | $81.13 | $364.9K | 0 |
| Dec 2, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 4,498 | $81.13 | $364.9K | 0 |
| Nov 9, 2022↗ | Powell Ann | EVP, Chief Human Resources | Sell | 16,250 | $80.45 | $1.31M | 0 |
| Nov 7, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 45,910 | $78.88 | $3.62M | 0 |
| Sep 20, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $69.71 | $1.74M | 0 |
| Sep 15, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 50,000 | $71.84 | $3.59M | 0 |
| Sep 14, 2022↗ | Powell Ann | EVP, Chief Human Resources | Sell | 25,000 | $70.75 | $1.77M | 0 |
| Sep 13, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 133,951 | $71.30 | $9.55M | 0 |
| Jul 1, 2022↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 4,786 | $76.84 | $367.8K | 0 |
| Jul 1, 2022↗ | Weese Michelle | EVP, Corporate Affairs | Sell | 682 | $76.84 | $52.4K | 0 |
| Jun 13, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 30,000 | $74.04 | $2.22M | 0 |
| Jun 6, 2022↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 65,000 | $74.89 | $4.87M | 0 |
| Apr 1, 2022↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 3,333 | $73.82 | $246.0K | 0 |
| Mar 21, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $71.52 | $1.79M | 0 |
| Mar 16, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 74,559 | $69.25 | $5.16M | 0 |
| Mar 14, 2022↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 29,532 | $69.20 | $2.04M | 0 |
| Mar 14, 2022↗ | Santiago Karen Murphy | SVP & Controller | Sell | 6,577 | $69.20 | $455.1K | 0 |
| Mar 10, 2022↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 34,545 | $68.42 | $2.36M | 0 |
| Mar 10, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 158,890 | $68.42 | $10.87M | 0 |
| Mar 10, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 9,222 | $68.42 | $631.0K | 0 |
| Mar 10, 2022↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 5,205 | $68.42 | $356.1K | 0 |
| Mar 10, 2022↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 44,901 | $68.42 | $3.07M | 0 |
| Mar 10, 2022↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 1,875 | $68.42 | $128.3K | 0 |
| Mar 10, 2022↗ | Powell Ann | EVP, Chief Human Resources | Sell | 20,369 | $68.42 | $1.39M | 0 |
| Mar 10, 2022↗ | Santiago Karen Murphy | SVP & Controller | Sell | 6,223 | $68.42 | $425.8K | 0 |
| Mar 10, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 8,751 | $68.42 | $598.7K | 0 |
| Mar 1, 2022↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 10,381 | $68.63 | $712.4K | 0 |
| Mar 1, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 10,303 | $68.63 | $707.1K | 0 |
| Feb 24, 2022↗ | Caforio Giovanni | Board Chair and CEO | Sell | 30,000 | $67.00 | $2.01M | 0 |
| Feb 4, 2022↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 1,312 | $64.99 | $85.3K | 0 |
| Dec 31, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 24,246 | $62.35 | $1.51M | 0 |
| Dec 31, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 23,033 | $62.35 | $1.44M | 0 |
| Dec 16, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 19,298 | $61.99 | $1.20M | 0 |
| Dec 2, 2021↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 1,350 | $55.41 | $74.8K | 0 |
| Dec 2, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 4,498 | $55.41 | $249.2K | 0 |
| Dec 2, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 4,498 | $55.41 | $249.2K | 0 |
| Nov 22, 2021↗ | von Autenried Paul | EVP, Chief Information Officer | Sell | 51,134 | $57.18 | $2.92M | 0 |
| Sep 20, 2021↗ | Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $60.64 | $1.52M | 0 |
| Aug 12, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 99,691 | $66.95 | $6.67M | 0 |
| Aug 3, 2021↗ | Powell Ann | EVP, Chief Human Resources | Sell | 23,280 | $68.57 | $1.60M | 0 |
| Aug 2, 2021↗ | Caforio Giovanni | Chairman and CEO | Sell | 20,000 | $68.58 | $1.37M | 0 |
| Aug 1, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 23,736 | $67.87 | $1.61M | 0 |
| Jul 30, 2021↗ | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Sell | 2,466 | $67.90 | $167.4K | 0 |
| Jul 30, 2021↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 29,390 | $68.04 | $2.00M | 0 |
| Jul 30, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 158,393 | $68.07 | $10.78M | 0 |
| Jul 30, 2021↗ | von Autenried Paul | EVP, Chief Information Officer | Sell | 25,000 | $68.06 | $1.70M | 0 |
| Jul 1, 2021↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 4,786 | $66.56 | $318.6K | 0 |
| Jul 1, 2021↗ | Santiago Karen Murphy | SVP & Controller | Sell | 547 | $66.56 | $36.4K | 0 |
| Jun 3, 2021↗ | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 738 | $64.80 | $47.8K | 0 |
| May 10, 2021↗ | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 1,118 | $65.00 | $72.7K | 0 |
| May 10, 2021↗ | Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | Sell | 15,000 | $65.25 | $978.8K | 0 |
| May 8, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 7,994 | $64.44 | $515.1K | 0 |
| May 5, 2021↗ | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Sell | 3,119 | $64.21 | $200.3K | 0 |
| May 5, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 30,546 | $64.29 | $1.96M | 0 |
| Apr 1, 2021↗ | Mily Elizabeth | EVP, Strategy & BD | Sell | 2,952 | $62.93 | $185.8K | 0 |
| Mar 22, 2021↗ | Caforio Giovanni | Chairman and CEO | Sell | 25,000 | $62.20 | $1.55M | 0 |
| Mar 10, 2021↗ | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Sell | 12,851 | $60.93 | $783.0K | 0 |
| Mar 10, 2021↗ | Caforio Giovanni | Chairman and CEO | Sell | 112,233 | $60.93 | $6.84M | 0 |
| Mar 10, 2021↗ | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Sell | 1,910 | $60.93 | $116.4K | 0 |
| Mar 10, 2021↗ | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 2,192 | $60.93 | $133.6K | 0 |
| Mar 10, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 4,329 | $60.93 | $263.8K | 0 |
| Mar 10, 2021↗ | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Sell | 1,978 | $60.93 | $120.5K | 0 |
| Mar 10, 2021↗ | LEUNG SANDRA | EVP, General Counsel | Sell | 31,200 | $60.93 | $1.90M | 0 |
| Mar 10, 2021↗ | Powell Ann | EVP, Chief Human Resources | Sell | 14,329 | $60.93 | $873.1K | 0 |
| Mar 10, 2021↗ | Santiago Karen Murphy | SVP & Controller | Sell | 2,662 | $60.93 | $162.2K | 0 |
| Mar 10, 2021↗ | Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | Sell | 14,589 | $60.93 | $888.9K | 0 |
| Mar 10, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 3,505 | $60.93 | $213.6K | 0 |
| Mar 10, 2021↗ | von Autenried Paul | EVP, Chief Information Officer | Sell | 10,017 | $60.93 | $610.3K | 0 |
| Mar 1, 2021↗ | Elkins David V | EVP, Chief Financial Officer | Sell | 8,573 | $61.63 | $528.4K | 0 |
| Mar 1, 2021↗ | VESSEY RUPERT | EVP, Research & Early Dev. | Sell | 8,944 | $61.63 | $551.2K | 0 |
BMY Insiders
Similar Stocks to BMY
LLY
Eli Lilly and Company
$984.11+0.70%
$921.90B
JNJ
Johnson & Johnson
$241.86-0.07%
$583.29B
ABBV
AbbVie Inc.
$220.81-2.02%
$398.49B
MRK
Merck & Co., Inc.
$115.92+0.00%
$286.57B
AMGN
Amgen Inc.
$366.74-0.29%
$198.26B
GILD
Gilead Sciences, Inc.
$144.25-0.66%
$180.27B
PFE
Pfizer Inc.
$26.62-0.89%
$152.73B
BIIB
Biogen Inc.
$183.58-0.71%
$27.14B